ArticlePCN reports : psychiatry and clinical neurosciences2025
Increased use of attention-deficit/hyperactivity disorder drugs among children and adolescents with suicidal ideation: A real-world registry study in Japan.
Article in PCN reports : psychiatry and clinical neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Re-evaluating age-related attention-deficit/hyperactivity disorder (ADHD) symptom trajectories using the Japanese ADHD Rating Scale-5.PCN reports : psychiatry and clinical neurosciences · 2026Article
- Increased use of attention-deficit/hyperactivity disorder drugs among children and adolescents with suicidal ideation: A real-world registry study in Japan.PCN reports : psychiatry and clinical neurosciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Suicidality remains a significant clinical concern for individuals with attention-deficit/hyperactivity disorder (ADHD) receiving treatment with ADHD medications, especially children and adolescents. This retrospective cohort study examined the association between suicidal ideation and the initiation of ADHD medications among children and adolescents with ADHD. Methods: Using children's mental health registry data from the National Center for Global Health and Medicine, this study included 431 patients aged 5-15 years diagnosed with ADHD and recorded their use of ADHD medications up to 5 years after the diagnosis. The baseline assessment of suicidal ideation was based on Item 10 of the Depression Self-Rating Scale for Children. The primary outcome was the incidence of the initiation of ADHD medications within 3 months after the diagnosis of ADHD. Results: At baseline assessment, 143 (33.2%) of 431 patients with ADHD had suicidal ideation. Multivariable logistic regression models revealed that suicidal ideation, older age, and more severe ADHD symptoms were all associated with the initiation of ADHD medications within 3 months after the diagnosis. Conclusion: These results suggest that among children and adolescents with ADHD, caution and vigilant monitoring for suicidal ideation are crucial before initiating ADHD medications; follow-up is necessary according to the severity of their condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.